Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130687 · ClinicalTrials.gov registry record · NA
Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 106
- Enrollment target
NCT02130687 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 106 participants.
The verdict
NCT02130687, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 106 participants
- Enrollment target
Study Summary
In this study the investigators will test the hypothesis that dipeptidyl peptidase IV (DPP4) inhibition attenuates the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibition but not angiotensin receptor blockade or calcium channel blockade. The investigators further hypothesize that this effect is mediated by substance P.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Aprepitant
- OTHER Mixed Meal Test (MMT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2014-06 |
| Est. Completion | 2020-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02130687
The ClinicalTrials.gov registry entry for NCT02130687 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02130687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02130687 about?
NCT02130687 is a clinical study titled "Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure". In this study the investigators will test the hypothesis that dipeptidyl peptidase IV (DPP4) inhibition attenuates the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibition but not angiotensin receptor blockade or calcium channel blockade. The investigators further hypothesize th...
What is the current status of trial NCT02130687?
This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2014-06. Estimated completion is 2020-08.
What interventions are being tested in trial NCT02130687?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Aprepitant (DRUG), Mixed Meal Test (MMT) (OTHER).
Who is sponsoring clinical trial NCT02130687?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.